Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Anaplastic lymphoma kinase Stories

2013-01-21 10:27:56

CHOP researcher leads large multicenter gene sequencing study of neuroblastoma An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations–mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to...

2013-01-20 12:20:29

-- CHOP Researcher Leads Large, Multicenter Gene Sequencing Study of Neuroblastoma-- PHILADELPHIA, Jan. 20, 2013 /PRNewswire-USNewswire/ -- An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations--mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now...

2013-01-03 08:20:20

SUNNYVALE, Calif., Jan. 3, 2013 /PRNewswire/ -- Trimble (NASDAQ: TRMB) announced today that it has acquired privately-held ALK Technologies Inc. of Princeton, NJ, a global leader in routing, mapping, mileage and navigation technologies. ALK Technologies offers proprietary routing and international map-based solutions for transportation, logistics and mobile workforces. The addition of ALK® is expected to extend and complement Trimble's Transportation and Logistics product...

2012-11-28 08:30:30

REHOVOT, Israel, November 28, 2012 /PRNewswire/ -- BioView Ltd. (TASE: BIOV), announced today that they have entered into an agreement with Abbott to collaborate on the development of an automated scanning solution to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in patients with advanced non-small cell lung cancer (NSCLC). Under terms of the agreement BioView will perform the appropriate studies to obtain regulatory approval for its Duet Automated...

2012-11-05 08:30:51

LOS ANGELES, Nov. 5, 2012 /PRNewswire/ -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today the launch of testing for ROS1 gene rearrangements. Recently, the Massachusetts General Hospital Cancer Center ("MGH") published studies showing that ROS1 driven tumors are sensitive to the FDA approved drug XALKORI®(1) (crizotinib)(2) to treat non-small-cell lung cancer ("NSCLC") patients with ALK gene...

2012-10-24 11:26:45

ABBOTT PARK, Ill., Oct. 24, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it will expand the current CE-IVD product labeling for its Vysis(®) ALK Break Apart FISH Probe Kit, allowing the test to be marketed in the European Union as a companion diagnostic. The test is designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in advanced non-small cell lung cancer (NSCLC) patients who may be eligible for treatment with XALKORI (crizotinib), an oral...

2012-10-02 02:29:43

CAMBRIDGE, England, October 2, 2012 /PRNewswire/ -- Cytocell Ltd. today announced the availability of a new molecular cytogenetic test designed to identify the presence of gene rearrangements associated with a specific form of non-small-cell lung cancer (NSCLC). These rearrangements in a gene known as ROS1 (c-ros oncogene 1) have been implicated in the formation of cancerous tumors in patients with NSCLC. (Logo: http://photos.prnewswire.com/prnh/20120906/559436 )...

2012-08-13 15:50:34

A broken chromosome is like an unmoored beansprout circling in search of attachment. If a cell tries to replicate itself with broken chromosomes, the cell will be killed and so it would very much like to find its lost end. Often, it finds a workable substitute: another nearby chromosome. When a broken chromosome attaches to another, or when chromosomes use a similar process to exchange genetic material, you have a translocation — genes end up fused to other genes, encoding a new...

2012-07-11 14:47:35

A new drug combination could offer hope to children with neuroblastoma — one of the deadliest forms of childhood cancer — by boosting the effectiveness of a promising new gene-targeted treatment. Researchers at The Institute of Cancer Research in London have found a way to overcome the resistance of cancer cells to a drug called crizotinib, which recently showed positive early results in its first trial in children with cancer. Crizotinib has already been licensed by the US...

2012-05-29 02:26:31

SAN DIEGO, May 29, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported on a recently released publication in which the Sequenom MassARRAY® System (for research use only) was used in a groundbreaking independent study that detected the transforming fusion gene EML4/ALK in non-small cell lung cancer. The study was conducted by researchers at Kinki University in Japan and appears in the May online...